Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial

Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial
A combination of the immune checkpoint inhibitor Keytruda (pembrolizumab) and the melanoma therapy Mektovi (binimetinib) is safe and well-tolerated by people with advanced triple negative breast cancer, preliminary findings from a Phase 1/2 clinical trial show. Safety data from the Phase 1 portion of the trial was presented in the poster, "Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer," at the ASCO-SITC Clinical Immuno-Oncology Symposium on Feb. 6 in Orlando, Florida. The ongoing clinical trial (NCT03106415) initially enrolled 12 triple negative breast cancer patients whose cancer was locally advanced and inoperable, or had spread to distant regions in the body (metastatic), and who had received no more than three prior lines of therapy. (The term "triple negative" means that the cancer growth is not driven by estrogen, progesterone, or by the protein
Subscribe or to access all post and page content.